Background and Objectives. We compared the early cytogenetic response (CgR) to a combination of imatinib mesylate (Glivec(R), Novartis Pharma, Basel, Switzerland) and a pegylated form of human recombinant interferon-alpha2b (pegIFN-alpha2b, PegIntron(R), Schering Plough, Kenilworth, New Jersey, USA) with the relative risk, assessed according to either Sokal's or Euro scoring systems. Design and Methods. Seventy-seven patients with early chronic phase, previously untreated, Ph-positive chronic myeloid leukemia (CML) received a combination of imatinib mesylate (400 mg/day) and pegIFN-alpha2b (3 consecutive cohorts treated with 50, 100 or 150 mug/weekly). Fifty-seven patients have completed the first 6 months of treatment and are evaluable for Cgr. Results. After 6 months of treatment, the overall major CgR rate was 89% and 90% in low risk patients (Sokal's and Euro Score, respectively), 76 and 59% in intermediate risk and 23% and 17% in high risk patients. These differences were significant (p=0.0001 for Sokal's Score and 0.001 for the Euro Score). Interpretation and Conclusions. For the first time, these data suggest that the early CgR rate to an imatinib mesylate-based regimen is significantly risk-related.

Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia

LIBERATI, Anna Marina
2003

Abstract

Background and Objectives. We compared the early cytogenetic response (CgR) to a combination of imatinib mesylate (Glivec(R), Novartis Pharma, Basel, Switzerland) and a pegylated form of human recombinant interferon-alpha2b (pegIFN-alpha2b, PegIntron(R), Schering Plough, Kenilworth, New Jersey, USA) with the relative risk, assessed according to either Sokal's or Euro scoring systems. Design and Methods. Seventy-seven patients with early chronic phase, previously untreated, Ph-positive chronic myeloid leukemia (CML) received a combination of imatinib mesylate (400 mg/day) and pegIFN-alpha2b (3 consecutive cohorts treated with 50, 100 or 150 mug/weekly). Fifty-seven patients have completed the first 6 months of treatment and are evaluable for Cgr. Results. After 6 months of treatment, the overall major CgR rate was 89% and 90% in low risk patients (Sokal's and Euro Score, respectively), 76 and 59% in intermediate risk and 23% and 17% in high risk patients. These differences were significant (p=0.0001 for Sokal's Score and 0.001 for the Euro Score). Interpretation and Conclusions. For the first time, these data suggest that the early CgR rate to an imatinib mesylate-based regimen is significantly risk-related.
2003
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1006268
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 28
social impact